Adagene INC. 6-K Filing
Ticker: ADAG · Form: 6-K · Filed: Apr 2, 2026 · CIK: 0001818838
Sentiment: neutral
Filing Stats: 2,005 words · 8 min read · ~7 pages · Grade level 9.7 · Accepted 2026-04-02 06:59:59
Filing Documents
- tm2610619d1_6k.htm (6-K) — 57KB
- tm2610619d1_ex99-1.htm (EX-99.1) — 15KB
- tm2610619d1_ex99-2.htm (EX-99.2) — 50KB
- tm2610619d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- tm2610619d1_ex99-2img001.jpg (GRAPHIC) — 3KB
- 0001104659-26-038858.txt ( ) — 133KB
Forward-Looking Statements
Forward-Looking Statements The Company cautions that statements included in this report that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “look forward,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company’s plans to advance the development of its product candidates, the timing of achieving any development or regulatory milestones or reporting data or whether such milestones or data will be achieved or generated, including whether any new drug application will be submitted or accepted and the timing thereof, and the potential of such product candidates, including to achieve any benefit, improvement, differentiation, trend or profile or any product approval or be effective. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual data may differ materially from those set forth in this report due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F filed with the SEC on April 1, 2026, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after t
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Adagene Inc. By: /s/ Peter Luo Name: Peter Luo Title: Chief Executive Officer Date: April 2, 2026 EXHIBIT INDEX Exhibit Description 99.1 Press release titled “Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) ” 99.2 Press release titled “Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA ® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response”